Cancer Treatment Today

Lay Summary: IVIG is standard for ITP but represents a "holding action" rather than a cure. IVIG is approved by the FDA for use in the treatment of the following diseases: Kawasaki disease, dermato/polymyositis, idiopathic thrombocytopenic purpura (ITP), Guillain-Barre syndrome, polyneuropathy, some viral diseases, and some forms of immune deficiency. The place of IVIG in the treatment of ITP is not well clarified. It does not modify the disease

Aplastic Anemia is considered to be among the diseases for which the Plan considers IVIG to experimental. Unfortunately there is very little supporting literature. A 2007 review found 7 reported cases, all of which responded to IVIG, but upon a closer look the review authors found that only 2 of the cases met criteria for true Aplastic Anemia. A 2007 guideliens (Anderson et al) concluded that : "There is no evidence to support the use of IVIG in